AA
CADL icon

ALPS Advisors’s Candel Therapeutics CADL Stock Holding History

ALPS Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$766K Buy
74,363
+14,734
+25% +$111K ﹤0.01% 771
2026
Q1 		$292K Buy
59,629
+14,550
+32% +$79.2K ﹤0.01% 978
2025
Q4 		$255K Buy
45,079
+18,801
+72% +$101K ﹤0.01% 953
2025
Q3 		$134K Sell
26,278
-767
-3% -$4.43K ﹤0.01% 1016
2025
Q2 		$137K Buy
+27,045
New +$139K ﹤0.01% 1022

Other funds holding CADL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return
TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.15B AUM 19.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $294M AUM 37.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

ALPS Advisors's CADL Position: Q2 2026 in Review

ALPS Advisors increased its Candel Therapeutics (CADL) stake by 25% in Q2 2026, buying an estimated $111K and bringing the position to 74,363 shares worth $766K. The position accounts for ﹤0.01% of the portfolio, ranked #771.

ALPS Advisors first reported a position in CADL in Q2 2025 and has held it in 5 quarters since. 46 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • ALPS Advisors held 74,363 shares of Candel Therapeutics worth $766K as of Q2 2026.
  • ALPS Advisors bought 14,734 Candel Therapeutics shares in Q2 2026, an estimated $111K.
  • Candel Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #771 holding.
  • ALPS Advisors first reported a position in Candel Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 46 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.